All Stories

  1. Gender differences in hepatitis C virus incidence in and out of opioid agonist treatment among people who inject drugs in Montréal, Canada, March 2011–March 2024
  2. Factors Associated With Adult Incarceration Among People With Opioid Use Disorder in New South Wales, Australia
  3. Global coverage of interventions for reduction of injecting drug use-related harm, HIV, viral hepatitis and tuberculosis in prisons and other carceral settings: A systematic review
  4. The global epidemiology of injecting drug use, HIV, viral hepatitis and tuberculosis among people who are incarcerated: a multistage systematic review
  5. The impact of HIV stigma and discrimination on HIV testing, antiretroviral treatment, and viral suppression in Africa: a pooled analysis of population-based surveys
  6. Initiation, cessation and resumption of attendance at the Melbourne supervised injecting room among a cohort of people who inject drugs
  7. Gender differences in social networks of women and men who inject drugs in Kenya
  8. Non-randomised trial of a hepatitis C same-day test and treat model using antibody test only for people who inject drugs in Armenia, Georgia and Tanzania: a CUTTS HepC study protocol
  9. Differences in sexual risk behaviours, HIV care utilisation and experiences of stigma between transgender women and cisgender men who have sex with men: findings from integrated biobehavioural surveys in Ukraine 2013–2018
  10. Modelling the impact of underage and coerced entry into sex work on HIV transmission in Tijuana, Mexico
  11. Identifying priority populations for HIV interventions using acquisition and transmission indicators: a combined analysis of 15 mathematical models from ten African countries
  12. Leveraging injection networks to prevent HIV and other blood borne infections among people who inject drugs in Kenya: design and rationale
  13. Preferences for harm reduction vending machine design among rural people who use drugs
  14. Differential risk for Hepatitis C and HIV among people who inject drugs in Kenya: a latent class analysis signaling needs for innovation in service delivery
  15. Characterising benzodiazepine use and the association with non-fatal overdose among people who inject opioids in England, Wales and Northern Ireland
  16. Has the HCV cascade of care changed among people who inject drugs in England since the introduction of direct-acting antivirals?
  17. The impact of cuts in the US President's Emergency Plan for AIDS Relief funding for HIV pre-exposure prophylaxis in sub-Saharan Africa: a modelling study
  18. Modeling the impact of changing drug markets and structural determinants on HCV and/or HIV transmission among people who inject drugs in the United States: A rural and urban comparison
  19. Impact and cost-effectiveness of interventions to eliminate hepatitis C virus among people who inject drugs in Haiphong, Vietnam
  20. Leveraging Injection Networks to Prevent HIV and Other Blood Borne Infections Among People Who Inject Drugs in Kenya: Design and Rationale
  21. Correction to: What Is the Optimal Community-Based Tuberculosis Screening Algorithm for People Who Inject Drugs in a High-Burden Setting?
  22. Global, regional, and national estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a multi-stage analysis
  23. What Is the Optimal Community-Based Tuberculosis Screening Algorithm for People Who Inject Drugs in a High-Burden Setting?
  24. Identifying priority populations for HIV interventions using acquisition and transmission indicators: a combined analysis of 15 mathematical models from 10 African countries
  25. Tuberculosis and people who use drugs: why focus on this overlooked population is important and why adapted interventions are necessary
  26. Supervised Injecting Room Cohort Study (SIRX): study protocol
  27. Imprisonment Among People who Use Methamphetamine in Victoria, Australia: A Prospective Cohort Study
  28. HIV incidence and factors associated with HIV risk among people who inject drugs engaged with harm-reduction programmes in four provinces in South Africa: a retrospective cohort study
  29. From conceptualising to modelling structural determinants and interventions in HIV transmission dynamics models: a scoping review and methodological framework for evidence-based analyses
  30. Modeling the impact of the COVID-19 pandemic on achieving HCV elimination amongst young and unstably housed people who inject drugs in San Francisco
  31. Sex and gender differences in hepatitis C virus risk, prevention, and cascade of care in people who inject drugs: systematic review and meta-analysis
  32. Testing and Treatment Interventions in Community Settings Key to Controlling a Recent Human Immunodeficiency Virus Outbreak Among People Who Inject Drugs in Glasgow: A Modeling Study
  33. Mathematical models of COVID-19 vaccination in high-income countries: A systematic review
  34. Kentucky Outreach Service Kiosk (KyOSK) Study protocol: a community-level, controlled quasi-experimental, type 1 hybrid effectiveness study to assess implementation, effectiveness and cost-effectiveness of a community-tailored harm reduction kiosk on H...
  35. Trends and factors associated with illicit drug use in South Africa: Findings from multiple national population-based household surveys, 2002–2017
  36. Comparison of Empirically Derived and Model-Based Estimates of Key Population HIV Incidence and the Distribution of New Infections by Population Group in Sub-Saharan Africa
  37. Measuring HIV Acquisitions Among Partners of Key Populations: Estimates From HIV Transmission Dynamic Models
  38. Scale-up of Direct-Acting Antiviral Treatment in Prisons Is Both Cost-effective and Key to Hepatitis C Virus Elimination
  39. Antibiotics do not induce expression of acrAB directly but via a RamA-dependent pathway
  40. Eliminating HIV in the UK among men who have sex with men
  41. Exposure of Escherichia coli to antibiotic-efflux pump inhibitor combinations in a pharmacokinetic model: impact on bacterial clearance and drug resistance
  42. Associations Between Sexual Behavior Stigma and HIV Risk Behaviors, Testing, Treatment, and Infection Among Men Who have Sex with Men in Ukraine
  43. Incarceration history is associated with HIV infection among community‐recruited people who inject drugs in Europe: A propensity‐score matched analysis of cross‐sectional studies
  44. Mortality among individuals prescribed opioid-agonist therapy in Scotland, UK, 2011–20: a national retrospective cohort study
  45. Impact of HCV Testing and Treatment on HCV Transmission Among Men Who Have Sex With Men and Who Inject Drugs in San Francisco: A Modelling Analysis
  46. Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis
  47. Trends in HIV incidence following scale-up of harm reduction interventions among people who inject drugs in Kachin, Myanmar, 2008–2020: analysis of a retrospective cohort dataset
  48. Modelling the impact and cost‐effectiveness of non‐governmental organizations on HIV and HCV transmission among people who inject drugs in Ukraine
  49. The population impact of herpes simplex virus type 2 (HSV-2) vaccination on the incidence of HSV-2, HIV and genital ulcer disease in South Africa: a mathematical modelling study
  50. Predictors of hepatitis C cure among people who inject drugs treated with directly observed therapy supported by peer case managers in Kenya
  51. Impact and cost‐effectiveness of the national scale‐up of HIV pre‐exposure prophylaxis among female sex workers in South Africa: a modelling analysis
  52. Interventions to prevent HIV and Hepatitis C among people who inject drugs: Latest evidence of effectiveness from a systematic review (2011 to 2020)
  53. Prison‐based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: a modelling study
  54. Modelling the impact of HIV and hepatitis C virus prevention and treatment interventions among people who inject drugs in Kenya
  55. Impact and cost-effectiveness of non-governmental organizations on the HIV epidemic in Ukraine among MSM
  56. A cross‐sectional study comparing men who have sex with men and inject drugs and people who inject drugs who are men and have sex with men in San Francisco: Implications for HIV and hepatitis C virus prevention
  57. Methods and indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by WHO
  58. Hepatitis C treatment outcomes among people who inject drugs accessing harm reduction settings in Kenya
  59. The contribution of unstable housing to HIV and hepatitis C virus transmission among people who inject drugs globally, regionally, and at country level: a modelling study
  60. Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and central Asia: a modelling analysis
  61. Evaluating the impact and cost-effectiveness of scaling-up HCV treatment among people who inject drugs in Ukraine
  62. Comparing men who have sex with men and inject drugs and people who inject drugs who are men and have sex with men in San Francisco: Implications for HIV and hepatitis C virus prevention
  63. Univariable associations between a history of incarceration and HIV and HCV prevalence among people who inject drugs across 17 countries in Europe 2006 to 2020 – is the precautionary principle applicable?
  64. Modeling the population‐level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia
  65. Modelling the impact of HIV and HCV prevention and treatment interventions for people who inject drugs in Dar es Salaam, Tanzania
  66. Diversity of incarceration patterns among people who inject drugs and the association with incident hepatitis C virus infection
  67. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison
  68. Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP‐C Treatment as Prevention Study in Prisons
  69. An intensive model of care for hepatitis C virus screening and treatment with direct‐acting antivirals in people who inject drugs in Nairobi, Kenya: a model‐based cost‐effectiveness analysis
  70. Overlapping Key Populations and HIV Transmission in Tijuana, Mexico: A Modelling Analysis of Epidemic Drivers
  71. Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis
  72. Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis
  73. Epidemiology and transmission of COVID-19 in cases and close contacts in Georgia in the first four months of the epidemic
  74. Modelling the Impact of Prevention and Treatment Interventions on HIV and Hepatitis C Virus Transmission Among People Who Inject Drugs in Kenya
  75. Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky
  76. Estimating the contribution of key populations towards HIV transmission in South Africa
  77. Is contact between men who have sex with men and non‐governmental organizations providing harm reduction associated with improved HIV outcomes?
  78. Injecting risk behaviours amongst people who inject drugs: A global multi-stage systematic review and meta-analysis
  79. Has resourcing of non‐governmental harm‐reduction organizations in Ukraine improved HIV prevention and treatment outcomes for people who inject drugs? Findings from multiple bio‐behavioural surveys
  80. Socio-demographic and ecological factors associated with anti-HCV prevalence in people who inject drugs: A systematic review
  81. Global systematic review and ecological analysis of HIV in people who inject drugs: National population sizes and factors associated with HIV prevalence
  82. Frequency of injecting among people who inject drugs: A systematic review and meta-analysis
  83. Associations between national development indicators and the age profile of people who inject drugs: results from a global systematic review and meta-analysis
  84. Prevalence and burden of HBV co‐infection among people living with HIV: A global systematic review and meta‐analysis
  85. The prevalence of non-fatal overdose among people who inject drugs: A multi-stage systematic review and meta-analysis
  86. Global patterns of opioid use and dependence: harms to populations, interventions, and future action
  87. Scaling Up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States: A Rural and Urban Comparison
  88. Inflammation, Glutamate, and Cognition in Bipolar Disorder Type II: A Proof of Concept Study
  89. A global meta-analysis on HIV, hepatitis C and hepatitis B among people who inject drugs – do gender differences vary by country-level indicators?
  90. Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis
  91. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs
  92. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review
  93. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland
  94. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia
  95. The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?
  96. Public health and international drug policy
  97. Incarceration of People who inject Drugs – Modelling its Role in HCV Transmission and the Impact of Scaled-Up HCV Treatment in Prisons
  98. The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments
  99. P076: The role of a hepatitis C virus vaccine: modelling the benefits alongside direct‐acting antiviral treatments